CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients-MedSci.cn

CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Zhang, HY; Local, A; Tyner, JW; Kurtz, SE; Wilmot, B; Mcweeney, S; Druker, BJ; Howell, SB; Rice, WG

CANCER RESEARCH, 2019; 79 (13):

科室
- - 订阅+
  - 更多科室
工具
服务